Physician profile

Carl A Smart

Pulmonary Disease · Monroe, NC

NPI 1518986652

$33,954.00

in general payments reported to CMS, 2019-2025

38 companies · $2,248 in 2025

The $2,248 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,983.40
Education$113.31

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $27,563.00 2020-2025 Fasenra, Tezspire, Airsupra
Glaxosmithkline, LLC. $1,634.44 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Amgen INC. $848.07 2021-2025 Tezspire
Genzyme Corporation $803.08 2023-2025
Mylan Specialty L.P. $354.88 2019-2024 Yupelri
Regeneron Healthcare Solutions, INC. $312.41 2021-2025 Dupixent
Philips North America LLC $301.74 2019-2025 Vest Therapy Und
Insmed, INC. $194.53 2019-2025 Arikayce, Brinsupri
Mallinckrodt Hospital Products INC. $174.48 2023-2024 Acthar
Baxter Healthcare $168.62 2022-2023 Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care
Grifols USA, LLC $157.23 2020-2025 Prolastin-C Liquid, Xembify
Ani Pharmaceuticals, INC. $150.98 2023-2025 Purified Cortrophin Gel
Actelion Pharmaceuticals US, INC. $118.81 2023-2024 Opsumit, Uptravi
Takeda Pharmaceuticals U.S.A., INC. $115.82 2023-2025 Glassia, Cuvitru
Inspire Medical Systems, INC. $113.31 2024-2025 Inspire
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Inogen, INC. $111.99 2023-2025 Inogen One G5 Oxygen Concentrator - Bluetooth
Boehringer Ingelheim Pharmaceuticals, INC. $105.32 2021-2025 Spiriva Respimat, Stiolto Respimat, Jascayd
Novartis Pharmaceuticals Corporation $85.49 2023-2024
Paratek Pharmaceuticals, INC. $79.00 2022-2024 Nuzyra
Genentech USA, INC. $66.63 2022-2023 Xolair
E.R. Squibb & Sons, L.L.C. $56.34 2021-2023
Advanced Respiratory, INC $45.13 2021
Pulmonx Corporation $40.49 2023-2025 Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter
Lilly USA, LLC $39.48 2025 Zepbound
Phadia US INC. $39.31 2022
Aytu Biopharma, INC. $35.77 2023 Karbinal
Electromed, INC. $30.42 2024-2025 Smartvest
Verona Pharma, INC. $27.47 2025 Ohtuvayre
Csl Behring $24.37 2020
Viatris Specialty LLC $23.16 2025 Yupelri
Vifor Pharma, INC. $22.18 2025 Zemaira
Hikma Pharmaceuticals USA $19.78 2024 Ryaltris
Bayer Healthcare Pharmaceuticals INC. $18.86 2023
Nabriva Therapeutics, Plc $16.62 2022
Circassia INC. $15.88 2019
Tactile Systems Technology INC $13.52 2025 Flexitouch Plus, Nimbl
Resmed Corp $13.32 2023
Mylan Pharmaceuticals INC. $12.07 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carl A Smart

$33,954.00

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $2,248 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/114607/carl-a-smart

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.